On Thursday, April 22, shares in Lipum will be traded on the Nasdaq First North Growth Market for the very first time.
The company will ring Nasdaq’s opening bell, which has been specially transported to Umeå, to mark the occasion.
Begin clinical trials in the spring of 2022
Lipum has developed a biological drug candidate which aims to offer better treatments for children with rheumatism. Pre-clinical studies have shown very promising results, and production development is ongoing.
“We will begin clinical trials in the spring of 2022, which means that we are at a late stage of our pre-clinical development. In parallel with the clinical development we aim to produce additional pre-clinical data relating to more diseases than just rheumatism. Our goal then is to establish collaborations with larger companies for the treatment of various chronic inflammatory diseases,” says Einar Pontén, CEO of Lipum.
Raised SEK 85 million
“We have raised approximately SEK 85 million through a new share issue, with the opportunity to receive an additional SEK 60 million in August 2022 via share options. In addition to gaining access to venture capital, we are also becoming more widely known. And now, as we become a public company, we must strive to become even better. It’s something that really motivates us,” says Pontén. “We are of course elated to have reached this milestone. It is proof that we are a well-organised company with a clear business idea that many others want to have an interest in.”
Photo of the Lipum team